115 Publications (Page 3 of 5)
2012
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results
Choueiri, Toni KChoueiri, Toni KVaishampayan, Ulka NVaishampayan, Ulka NRosenberg, Jonathan ERosenberg, Jonathan ELogan, TheodoreLogan, TheodoreHarzstark, Andrea LynneHarzstark, Andrea LynneRini, Brian IRini, Brian ISrinivas, SandySrinivas, SandyAdams, Laurel MAdams, Laurel MSherman, Laurie JillSherman, Laurie JillOttesen, Lone HarildOttesen, Lone HarildMcDermott, David FMc Dermott, David FBottaro, Donald PBottaro, Donald PLinehan, W MarstonLinehan, W. MarstonSrinivasan, Ramaprasad and Srinivasan, Ramaprasad
Journal of Clinical Oncology, vol. 30, (no. 5_suppl), pp. 355, 2012-02-10. | Journal Article
 
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
Bruce, Justine YBruce, JustineBruce, JustineEickhoff, JensEickhoff, JensEickhoff, JensPili, RobertoPili, RobertoPili, RobertoLogan, TheodoreLogan, TheodoreLogan, TheodoreCarducci, MichaelCarducci, MichaelCarducci, MichaelArnott, JamieArnott, JamieArnott, JamieTreston, AnthonyTreston, AnthonyTreston, AnthonyWilding, GeorgeWilding, GeorgeWilding, GeorgeLiu, GlennLiu, Glenn and Liu, Glenn
Investigational New Drugs, vol. 30, (no. 2), pp. 794-802, Apr 2012. | Journal Article
 
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644)
Srinivasan, RamaprasadSrinivasan, RamaprasadBottaro, Donald PBottaro, Donald PChoueiri, Toni KChoueiri, Toni KVaishampayan, Ulka NVaishampayan, Ulka NRosenberg, Jonathan ERosenberg, Jonathan ELogan, TheodoreLogan, TheodoreHarzstark, Andrea LynneHarzstark, Andrea LynneRini, Brian IRini, Brian ISrinivas, SandySrinivas, SandyAdams, Laurel MAdams, Laurel MLaubscher, KevinLaubscher, KevinOttesen, Lone HarildOttesen, Lone HarildMc Dermott, David FMcDermott, David FLinehan, W. Marston and Linehan, W Marston
Journal of Clinical Oncology, vol. 30, (no. 5_suppl), pp. 372, 2012-02-10. | Journal Article
 
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Margolin, KimMargolin, KimErnstoff, Marc SErnstoff, Marc SHamid, OmidHamid, OmidLawrence, DonaldLawrence, DonaldMc Dermott, David FMc Dermott, DavidPuzanov, IgorPuzanov, Igor JWolchok, JeddWolchok, Jedd DClark, Joseph IClark, JosephSznol, MarioSznol, MarioLogan, Theodore FLogan, Theodore FRichards, JonRichards, JonMichener, TracyMichener, TracyBalogh, AgnesBalogh, AgnesHeller, Kevin NHeller, Kevin NHodi, F S and Hodi, F S
The lancet oncology, vol. 13, (no. 5), pp. 459-65, 2012/May. | Journal Article
 
Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group)
Hutson, Thomas EDang, Long HLauer, Richard CStarodub, AlexanderHauke, Ralph JLogan, TheodoreBylow, Kathryn AGalsky, Matt DBibby, David CKremmidiotis, GabrielDoolin, Elizabeth ELavranos, Tina CLeske, Annabell FHahn, Noah MSonpavde, GuruSweeney, Christopher and Sarantopoulos, John
Journal of Clinical Oncology, vol. 30, (no. 5_suppl), pp. 373, 2012-02-10. | Journal Article
 
Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).
Figlin, Robert AAmin, AsimDudek, ArkadiuszLogan, TheodoreLance, Raymond SHolzbeierlein, Jeffrey MMaster, Viraj APal, Sumanta KumarGamble, Alicia HDeBenedette, MarkTcherepanova, Irina YWilliams, W LeePlessinger, DougMiesowicz, Fred and Nicolette, Charles A
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 30, (no. 5_suppl), pp. 348, February 10, 2012. | Journal Article
 
Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors
Hutson, Thomas EDang, Long HLauer, Richard CStarodub, AlexanderHauke, Ralph JGalsky, Matt DBylow, Kathryn ALogan, TheodoreCowey, Charles LanceBibby, David CKremmidiotis, GabrielDoolin, Elizabeth ELavranos, Tina CSonpavde, GuruHahn, Noah MSweeney, Christopher and Sarantopoulos, John
Journal of Clinical Oncology, vol. 30, (no. 15_suppl), pp. 4603, 2012-05-20. | Journal Article
 
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
Ribas, AntoniChesney, Jason AGordon, Michael SAbernethy, Amy PLogan, Theodore FLawson, David HChmielowksi, BartoszGlaspy, John ALewis, KarlHuang, BoWang, ErjianHsyu, Poe-HirrGomez-Navarro, JesusGerhardt, DianaMarshall, Margaret A and Gonzalez, Rene
Journal of translational medicine, vol. 10, pp. 236, 2012. | Journal Article
2011
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto, Jose PHudes, Gary RDutcher, Janice PLogan, Theodore FWhite, Charles SKrygowski, MizueCincotta, MariaShapiro, MarkDuran, Ignacio and Berkenblit, Anna
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 29, (no. 13), pp. 1750-6, 2011/May/1. | Journal Article
2010
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin (alpha sub v)(beta sub 3), (plus or minus) dacarbazine in patients with stage IV metastatic melanoma
Hersey, PeterGonzalez, ReneO'Day, StevenWeber, RobertBedikian, AgopSosman, JeffreyKirkwood, JohnHammershaimb, LuzRichards, JonSharfman, WilliamLogan, Theodore and Buzoianu, Manuela
Cancer, vol. 116, (no. 6), pp. 1526, 20100315. | Journal Article
 
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Hersey, PeterSosman, Jeffrey AO'Day, StevenRichards, JonBedikian, Agop YGonzalez, ReneSharfman, WilliamWeber, RobertLogan, Theodore FBuzoianu, ManuelaHammershaimb, Luz and Kirkwood, John M
Cancer, vol. 116, (no. 6), pp. 1526-34, 2010/Mar/15. | Journal Article
2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
Tarhini, AhmadMillward, MichaelMainwaring, PaulKefford, RichardLogan, Theodore FPavlick, AnnaKathman, Steven JLaubscher, Kevin HDar, Mohammed M and Kirkwood, John M
Cancer, vol. 115, (no. 4), pp. 859-868, 2009. | Journal Article
 
Prognostic Implications of Polymorphisms and Interleukin-2 Therapy for Renal Cell Carcinoma
Gardner, Thomas AGardner, ThomasLogan, Theodore and Logan, Theodore
Journal of Urology, The, vol. 182, (no. 2), pp. 426, 2009. | Journal Article
2008
A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer
Robertson, Michael JKirkwood, John MLogan, Theodore FKoch, Kevin MKathman, StevenKirby, Lyndon CBell, William NThurmond, Linda MWeisenbach, Jill and Dar, Mohammed M
Clinical Cancer Research, vol. 14, (no. 11), pp. 3462-3469, 2008. | Journal Article
 
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Atkins, Michael BSosman, Jeffrey AAgarwala, SanjivLogan, TheodoreClark, JosephErnstoff, Marc SLawson, DavidDutcher, Janice PWeiss, GeoffreyCurti, Brendan and Margolin, Kim
Cancer, vol. 113, (no. 8), pp. 2139-45, 2008/Oct/15. | Journal Article
2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
Clark, JosephMehrabi, JessicaSosman, Jeffrey ALogan, Theodore FMargolin, KimDutcher, Janice PUrba, Walter JErnstoff, Marc SMc Dermott, David FLau, Ann M and Atkins, Michael B
Journal of immunotherapy (Hagerstown, Md. : 1997), vol. 30, (no. 8), pp. 839-46, 2007 Nov-Dec. | Journal Article
 
Urticaria and Angioedema in Renal Cell Cancer Patients Treated with IL-2
Logan, Theodore FStrippoli, Giovanni and Levine, Macy I
Cancer Investigation, vol. 25, (no. 7), pp. 584-588, 2007. | Journal Article
2006
Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study
Rini, Brian IRini, Brian IHalabi, SusanHalabi, SusanBarrier, RobertBarrier, RobertMargolin, KimMargolin, Kim AAvigan, David EAvigan, DavidLogan, TheodoreLogan, TheodoreStadler, Walter MStadler, Walter MMcCarthy, Philip LMcCarthy, Philip LLinker, Charles ALinker, Charles ASmall, Eric J and Small, Eric J
Biology of Blood and Marrow Transplantation, vol. 12, (no. 7), pp. 785, 2006. | Journal Article
 
Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer
Robertson, Michael JMier, James WLogan, Theodore FAtkins, Michael BKoon, Henry BKoch, Kevin MKathman, StevenPandite, Lini NOei, CoreenKirby, Lyndon CJewell, Roxanne CBell, William NThurmond, Linda MWeisenbach, JillRoberts, Suzanne and Dar, Mohammed M
Clinical Cancer Research, vol. 12, (no. 14), pp. 4265-4273, 2006. | Journal Article
 
Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.
Logan, Theodore F and Robertson, Michael J
Current oncology reports, vol. 8, (no. 2), pp. 114-9, 2006/Mar. | Journal Article
2005
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner, Jeffrey DSchauwecker, DonaldDavidson, DarrellLogan, TheodoreColeman, John JHutchins, GaryLove, CharleneWenck, Stacie and Daggy, Joanne
Cancer, vol. 104, (no. 3), pp. 570-9, 2005/Aug/1. | Journal Article
 
Inefficacy of F‐18 fluorodeoxy‐D‐glucose‐positron emission tomography scans for initial evaluation in early‐stage cutaneous melanoma
Wagner, Jeffrey DWagner, Jeffrey DWagner, Jeffrey DWagner, Jeffrey DSchauwecker, DonaldSchauwecker, DonaldSchauwecker, DonaldSchauwecker, DonaldDavidson, DarrellDavidson, DarrellDavidson, DarrellDavidson, DarrellLogan, TheodoreLogan, TheodoreLogan, TheodoreLogan, TheodoreColeman, John JColeman, John JColeman, John JColeman, John JHutchins, GaryHutchins, GaryHutchins, GaryHutchins, GaryLove, CharleneLove, CharleneLove, CharleneLove, CharleneWenck, StacieWenck, StacieWenck, StacieWenck, StacieDaggy, JoanneDaggy, JoanneDaggy, Joanne and Daggy, Joanne
Cancer, vol. 104, (no. 3), pp. 579, 1 August 2005. | Journal Article
 
Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies
Ascierto, PaoloScala, StefaniaCastello, GiuseppeDaponte, AntonioSimeone, EsterOttaiano, AlessandroBeneduce, GerardoRosa, VincenzoIzzo, FrancescoMelucci, MariaEnsor, C.Prestayko, ArchieHoltsberg, FrederickBomalaski, JohnClark, MikeSavaraj, NiramolFeun, Lynn and Logan, Theodore
Journal of Clinical Oncology, vol. 23, (no. 30), pp. 7668, 20051020. | Journal Article
 
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
Mc Dermott, David FRegan, Meredith MClark, JosephFlaherty, Lawrence EWeiss, Geoffery RLogan, Theodore FKirkwood, John MGordon, Michael SSosman, Jeffrey AErnstoff, Marc STretter, Christopher PUrba, Walter JSmith, John WMargolin, KimMier, James WGollob, Jared ADutcher, Janice P and Atkins, Michael B
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 23, (no. 1), pp. 133-41, 2005/Jan/1. | Journal Article
 
Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma
Burczynski, Michael ETwine, Natalie CDukart, GaryMarshall, BonnieHidalgo, ManuelStadler, Walter MLogan, Theodore FDutcher, JaniceHudes, Gary RTrepicchio, William LStrahs, AndrewImmermann, FredSlonim, Donna and Dorner, Andrew J
Clinical Cancer Research, vol. 11, (no. 3), pp. 1181-1189, 2005. | Journal Article